Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Liabilities and Shareholders Equity (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Liabilities and Shareholders Equity data on record, last reported at $30.6 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 4.39% year-over-year to $30.6 million; the TTM value through Sep 2025 reached $114.4 million, changed 0.36%, while the annual FY2024 figure was $26.7 million, 4.08% down from the prior year.
  • Liabilities and Shareholders Equity reached $30.6 million in Q3 2025 per NWBO's latest filing, up from $29.5 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $40.2 million in Q4 2021 and bottomed at $26.7 million in Q4 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $30.1 million, with a median of $29.3 million recorded in 2024.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 253.48% in 2021, then fell 22.0% in 2022.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $40.2 million in 2021, then fell by 22.0% to $31.3 million in 2022, then fell by 11.04% to $27.9 million in 2023, then fell by 4.08% to $26.7 million in 2024, then rose by 14.52% to $30.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $30.6 million in Q3 2025, $29.5 million in Q2 2025, and $27.5 million in Q1 2025.